PSMB8 and non-Hodgkin lymphoma: In agreement with this notion, CFZ at a dose that selectively inhibits both the CT-L active sites of β5 and LMP7 induced an anti-tumour response in MM, non-Hodgkin lymphoma (NHL) and leukaemia cells with minimal cytotoxic effects in non-transformed cells50.